Tim Watts, CEO of Shield Therapeutics #STX provides a U.S. update and confirms they remain on track to launch Accrufer® in the US by the end of June 2021.

Shield is a commercial stage, pharmaceutical company with a focus on addressing iron deficiency with its lead product Feraccru® /Accrufer® (ferric maltol), a novel, stable, non-salt based oral therapy for adults with iron deficiency with or without anaemia.

www.voxmarkets.co.uk